Assessing cancer drugs for reimbursement: Methodology, relationship between effect size and medical need;Critères et méthodologie d'évaluation au remboursement des anticancéreux

Therapie

Volumn 65, Issue 4, 2010, Pages

  De Sahb Berkovitch, Rima ^a   Woronoff Lemsi, Marie Christine ^b   Molimard, Mathieu ^c  

^a Roche   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer drugs; Criteria; Overall survival; Progression free survival; Reimbursement; Transparency Commission

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ASSESSMENT; COLORECTAL CANCER; DISEASE FREE SURVIVAL; EFFECT SIZE; HISTOLOGY; HUMAN; LUNG CANCER; LYMPHOMA; MEDICAL SERVICE; METHODOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REIMBURSEMENT; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; EUROPEAN UNION; HEALTH SERVICE; NEOPLASM; STANDARD; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; EUROPE; EUROPEAN UNION; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NEOPLASMS; SURVIVAL; TREATMENT OUTCOME;

EID: 78649671301     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/20010041     Document Type: Article

References (17)

1. EMEA. Guideline on the evaluation of anticancer medicinal products in man (CPMP/EWP/205/95 Rev.3/Corr.2, Dec 2005) http : //www.ema.europa. eu/pdfs/human/ewp/020595en.pdf
2. FDA. Guidance for industry, clinical trial endpoints for the approval, of cancer drugs and biologies (May 2007) http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm071590.pdf
3. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, et al. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 2008; 26: 3721-6
4. Pazdur R. Endpoints for assessing durg activity in clinical trials. Oncologist 2008; 13(suppl2): 1.9-21
5. Pignatti F, Aronso B, Vamvakas S, et al Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology. Critical Reviews in Oncology/Hematology 2002; 42: 123-35
6. Eisenhauer A, Therasse P, Bogaerts J, et al. New response evaluation, criteria in solid tumours: revised REGIST guideline (version 1.1). European Journal of Cancer 2009; 45: 228-47
7. Cheson B, Pfistner B, Juweid ME, et al. Revised response criteria for malignat lymphoma. J Clin Oncol 25: 579-86
8. Buyse M , Burzykowski T, Caroll K, et al. Progression-free survual is a sur- rogate for survival in advanced colorectal, cancer. J Clin Oncol 2007; 25: 5218-24
9. Punt C.J, Buyse M, Könne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007; 99: 998-1003
10. Sargent D, Wieand H, Haller D, et al. Disease-free survival Versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient, data from 20,898 Patients on 18 randomized Trials. J Clin Oncol 2005; 23: 8664-70
11. Tang P, Bentzen S, Chen E, et al. Surrogate end points for median overall survival in metastatic colorectal, cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25: 4562-8
12. Hudis C, Barlow W, Costantino J, et al. Proposal, for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system, J Clin Oncol 2007; 25: 2127-32
13. Miksad R, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J of Technol Assess Health Care 2008; 24 (4): 371-83
14. Knox J. Progression-free survival as endpoint in metastatic RCC? Comment n°559.157 The Lancet Vol 372 August 9, 2008
15. Freidlin B, Korn. E, Hunsberger S, et al. Proposal for the use of progressionfree survival in uriblinded randomized trial. J Clin Oncol 2007; 25: 2122-6
16. Fleming T, Rothman M and Lu H. Issues in using progression-free survival when evaluating oncology product. J Clin Oncol 2009; 27: 2874-80
17. Dodd L, Freidlin B, Jaffe C, et al. Blinded .independent central review of progression-free srvival in Phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 2008; 26: 3791-6